Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis.

Antoon JW, Hall M, Metropulos D, Steiner MJ, Jhaveri R, Lohr JA.

J Pediatr Pharmacol Ther. 2016 Sep-Oct;21(5):426-431.

2.

Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Rao K, Higgins PD.

Inflamm Bowel Dis. 2016 Jul;22(7):1744-54. doi: 10.1097/MIB.0000000000000793.

PMID:
27120571
3.

Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation.

Shin JY, Ko EJ, Lee SH, Shin JB, Kim SI, Kwon KS, Kim HG, Shin YW, Bang BW.

Intest Res. 2016 Jan;14(1):83-8. doi: 10.5217/ir.2016.14.1.83. Epub 2016 Jan 25.

4.

Rational Therapy of Clostridium difficile Infections.

Keller PM, Weber MH.

Viszeralmedizin. 2014 Oct;30(5):304-9. doi: 10.1159/000366302. Review.

5.

An agent-based simulation model for Clostridium difficile infection control.

Codella J, Safdar N, Heffernan R, Alagoz O.

Med Decis Making. 2015 Feb;35(2):211-29. doi: 10.1177/0272989X14545788. Epub 2014 Aug 11.

6.

Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review.

Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z.

Tech Coloproctol. 2014 Mar;18(3):223-32. doi: 10.1007/s10151-013-1081-0. Epub 2013 Nov 1. Review.

7.

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL.

Clin Infect Dis. 2011 Sep;53(5):440-7. doi: 10.1093/cid/cir404. Erratum in: Clin Infect Dis. 2011 Dec;53(12):1312. Dosage error in article text.

8.

Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, Valiquette L.

BMC Infect Dis. 2010 Dec 30;10:363. doi: 10.1186/1471-2334-10-363.

9.
10.

Future novel therapeutic agents for Clostridium difficile infection.

Koo HL, Garey KW, Dupont HL.

Expert Opin Investig Drugs. 2010 Jul;19(7):825-36. doi: 10.1517/13543784.2010.495386. Review.

11.

Clostridium difficile: The evolving story.

Johnston B, Conly J.

Can J Infect Dis Med Microbiol. 2007 Nov;18(6):341-5. No abstract available.

12.

An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.

Bailey P, Gray H.

Cases J. 2008 Aug 18;1(1):111. doi: 10.1186/1757-1626-1-111.

13.

Case-control analysis of clostridium difficile-associated diarrhea on a gynecologic oncology service.

Waggoner SE, Barter J, Delgado G, Barnes W.

Infect Dis Obstet Gynecol. 1994;2(4):154-61.

14.

A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Peppe J, Porzio A, Davidson DM.

Br J Clin Pharmacol. 2008 Jul;66(1):102-9. doi: 10.1111/j.1365-2125.2008.03151.x. Epub 2008 Mar 13.

15.

Clostridium difficile-associated colitis.

Hull MW, Beck PL.

Can Fam Physician. 2004 Nov;50:1536-40, 1543-5. Review. Erratum in: Can Fam Physician. 2005 Feb;51:192.

16.

Clostridium difficile-associated diarrhea in adults.

Poutanen SM, Simor AE.

CMAJ. 2004 Jul 6;171(1):51-8. Review.

17.

Managing antibiotic associated diarrhoea.

Barbut F, Meynard JL.

BMJ. 2002 Jun 8;324(7350):1345-6. No abstract available.

19.

Update on pseudomembranous colitis.

Silva J Jr.

West J Med. 1989 Dec;151(6):644-8. Review.

20.

In vitro synergy studies with Clostridium difficile.

Bacon AE, McGrath S, Fekety R, Holloway WJ.

Antimicrob Agents Chemother. 1991 Mar;35(3):582-3.

Supplemental Content

Support Center